Keybanc analyst Justin Patterson maintains Meta Platforms (NASDAQ:META) with a Overweight and raises the price target from $190 to $196.
Apyx Medical Corporation Announces Results Of The U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve The Appearance Of Lax Skin In The Neck And Submental Region; Says Primary Effectiveness Endpoint Of Study Was Met
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of
